A5029272729- Adrenal and Paraganglionic Tumors
- Cancer, Hypoxia, and Metabolism
- Glioma Diagnosis and Treatment
- Pituitary Gland Disorders and Treatments
- Bone health and treatments
- Bone health and osteoporosis research
- Hormonal Regulation and Hypertension
- Bone Metabolism and Diseases
- Prostate Cancer Treatment and Research
- Advanced Breast Cancer Therapies
- Nutrition and Health in Aging
- Lung Cancer Research Studies
- Neuroendocrine Tumor Research Advances
- Cervical Cancer and HPV Research
- Cancer Risks and Factors
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- COVID-19 and healthcare impacts
- Hormonal and reproductive studies
- Nutritional Studies and Diet
- Ultrasound in Clinical Applications
- Thyroid Cancer Diagnosis and Treatment
- Dietary Effects on Health
- Cancer Diagnosis and Treatment
- Viral-associated cancers and disorders
University of Brescia
2018-2025
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
2019-2025
Surgical Specialties (Canada)
2024
Brescia University
2024
The University of Texas MD Anderson Cancer Center
2024
Inserm
2021-2024
Université Paris-Saclay
2021-2024
Institut thématique Immunologie, inflammation, infectiologie et microbiologie
2023
Inflammation, Microbiome and Immunosurveillance
2021
Université Paris-Sud
2021
Adrenocortical carcinoma (ACC) has an aggressive but variable clinical course. Prognostic stratification based on the European Network for Study of Adrenal Tumours stage and Ki67 index is limited. We aimed to demonstrate prognostic role a points-based score (S-GRAS) in large cohort patients with ACC.This multicentre, retrospective study ACC who underwent adrenalectomy.The S-GRAS was calculated as sum following points: tumour (1-2 = 0; 3 1; 4 2), grade (Ki67 0-9% 10-19% ≥20% 2 points),...
Abstract Context Because of the rarity adrenocortical cancer (ACC), only a few population-based studies are available, and they reported limited details in characterization patients their treatment. Objective To describe nationwide cohort presentation with ACC, treatment strategies, potential prognostic factors. Methods Retrospective analysis 512 diagnosed 12 referral centers Italy from January 1990 to June 2018. Results ACC as incidentalomas accounted for overall 38.1% cases, frequency that...
Background . Trastuzumab emtansine (T-DM1), sacituzumab govitecan (SG), and trastuzumab deruxtecan (T-DXd) are three ADCs approved for the treatment of metastatic breast cancer (MBC). Since gastrointestinal toxicities have been commonly observed with these drugs in clinical trials, a pooled analysis evaluating adverse events (AEs) patients MBC treated trials was performed. Methods PubMed, Embase, Cochrane Library were searched from inception until May 2023 phase II III reporting frequency...
Etoposide, doxorubicin and cisplatin plus oral mitotane (EDP-M) comprise the reference regimen in management of patients with adrenocortical carcinoma (ACC). In this paper, we described outcome 58 advanced/metastatic ACC consecutively treated EDP-M a center for rare disease Italy. series, obtained partial response 50% patients; median progression free survival (PFS) overall were 10.1 months (95% Confidence Interval [CI 95%] 8.1–12.8) 18.7 CI: 14.6–22.8), respectively. was not interrupted...
International guidelines recommend local therapies (LTs) such as thermal ablation (LTA; radiofrequency, microwave, cryoablation), transarterial (chemo)embolisation (TA(C)E), and radioembolisation (TARE) therapeutic options for advanced adrenocortical carcinoma (ACC). However, the evidence these recommendations is scarce. We retrospectively analysed patients receiving LTs ACC. Time to progression of treated lesion (tTTP) was primary endpoint. The secondary endpoints were best objective...
Objective Temozolomide has shown a significant anti-proliferative activity on adrenocortical cancer (ACC) cells in vitro . Design On the basis of these results drug was prescribed as second/third line advanced metastatic ACC patients four referral centers Italy. Methods We retrospectively collected anagraphic, clinical and pathological data with disease progression to standard chemotherapy plus mitotane who were treated temozolomide at dose 200 mg/m 2 /die given for 5 consecutive days every...
Abstract Context We investigated the role of Gallium 68 dodecanetetraacetic acid Tyr3-octreotide (68Ga-DOTATOC) positron emission tomography/computed tomography (PET/CT) in detecting somatostatin receptors (SSTRs) 19 patients with metastatic adrenocortical carcinoma (ACC) and explored activity yttrium-90/lutetium-177 (90Y/177Lu-DOTATOC) peptide receptor radionuclide therapy (PRRT). Case description methods 68Ga uptake sites was scored terms intensity anatomical distribution standard value...
The reduction of lean body mass (LBM) and the increase fat (FBM) caused by androgen deprivation therapy (ADT) administered to prostate cancer patients are well known lead an increased risk sarcopenia. effects addition receptor pathway inhibitors (ARPIs) ADT on composition have not been studied thoroughly. BONENZA (NCT03336983) is a prospective phase 2 trial in which metastatic hormone-sensitive were randomized receive plus enzalutamide with (EZ arm) or without (E zoledronic acid. Total...
Importance Women with early breast cancer (EBC) exposed to aromatase inhibitors (AIs) may experience fragility fractures despite treatment bone-active drugs. Risk factors for in patients receiving AIs and denosumab have not been explored date. Objectives To evaluate whether an association exists between dual x-ray absorptiometry (DXA)–measured fat body mass (FBM) vertebral fracture (VF) progression postmenopausal women EBC undergoing adjuvant therapy combination examine VF was associated...
Abstract Background Bone health management in premenopausal women with breast cancer (BC) under hormone-deprivation therapies (HDTs) is often challenging, and the effectiveness of bone-active drugs still unknown. Methods This retrospective multicenter study included 306 early BC undergoing HDTs. mineral density (BMD) morphometric vertebral fractures (VFs) were assessed 12 months after HDT initiation then at least 24 months. Results After initial assessment, prescribed 77.5% (151 denosumab 60...
The prevalence of Skeletal Related Adverse Events (SREs) in EGFR mutated non-small cell lung cancer (NSCLC) patients with bone metastases, treated modern tyrosine kinase inhibitors (TKIs), has been scarcely investigated.We retrospectively evaluated the data NSCLC metastases TKIs 12 Italian centers from 2014 to 2019, primary aim explore type and frequency SREs.Seventy-seven out 274 enrolled (28%) developed at least one major SRE: 55/274 (20%) fractures, 30/274 (11%) spinal cord compression,...
Introduction Adrenocortical carcinoma (ACC) is a rare cancer that commonly spreads to the liver, lungs and lymph nodes. Bone metastases are infrequent. Objective The aim of this report was describe clinical characteristics, survival perspective, prognostic factors frequency adverse skeletal-related events (SREs) in patients with ACC who developed bone metastasis. Methods This retrospective, observational, multicenter, multinational study diagnosed from were treated followed up three European...
Mitotane is the only drug approved for treatment of adrenocortical carcinoma (ACC). The regimen to be added mitotane a chemotherapy including etoposide, doxorubicin, and cisplatin. This pharmacological approach, however, has limited efficacy significant toxicity. Evidence indicates that ACC seems sensitive alkylating agents. Trabectedin an anti-tumor acts as agent with complex mechanism action. Here, we investigated whether trabectedin could exert cytotoxic activity in vitro cell models ACC....
•Cabazitaxel is well tolerated but poorly active as second/third-line treatment in patients with advanced ACC.•Combining RECIST and Choi criteria could be of value the assessment disease response to chemotherapy ACC patients.•Older age, elevated cortisol LDH blood level correlate a greater risk death multivariate analysis. BackgroundAdrenocortical carcinoma (ACC) rare aggressive malignancy poor prognosis. No efficacious options are currently available for metastatic progression standard...
Triple-negative breast cancer (TNBC) is an aggressive subtype, owing to its high metastatic potential: Patients who develop brain metastases (BMs) have a poor prognosis due the lack of effective systemic treatments. Surgery and radiation therapy are valid options, while pharmacotherapy still relies on chemotherapy, which has limited efficacy. Among new treatment strategies available, antibody-drug conjugate (ADC) sacituzumab govitecan shown encouraging activity in TNBC, even presence BMs.A...
Adrenocortical cancer (ACC) is a rare malignancy with dismal prognosis. The treatment includes mitotane and EDP chemotherapy (etoposide, doxorubicin, cisplatin). However, new therapeutic approaches for advanced ACC are needed, particularly targeting the metastatic process. Here, we deepen role of progesterone as potential drug ACC, in line its antitumoral effect other cancers.NCI-H295R, MUC-1, TVBF-7 cell lines were used xenografted zebrafish embryos. Migration invasion studied using...
Abstract Purpose We aimed to investigate the role of a lifestyle intervention and clinical therapeutic factors for preventing weight gain in early breast cancer (BC) patients from one week before 12 months after chemotherapy. Methods Dietary assessments were conducted by trained dietician using food-frequency questionnaire at each assessment. Total energy, macronutrients intakes, physical activity estimated Mediterranean Diet Score (MDS) adherence diet was calculated. At follow-up visit,...
Human papillomaviruses (HPVs) are commensal viruses with pathogenic potential. Their life cycle requires the proliferation and differentiation of keratinocytes (KCs) to form pluristratified epithelia. Based on original organotypic epithelial raft cultures protocol, we provide an updated workflow optimally generate human epithelia supporting complete HPV replicative cycle, here called 3D full-thickness (3Deps). We describe steps for genome preparation, KC transfection, dermal equivalent...